Table 4.
Time to hCG Pregnancy by TSH and Antibody Status Among Women With Normal fT4 (0.7–1.85 ng/dL) in the EAGeR Trial
| Outcomes, N (%) | TSH fT4, 0.7–1.85 ng/dL |
Antithyroid Antibodies |
||
|---|---|---|---|---|
| <2.5 | ≥2.5 | Negative | Positive | |
| Total N | 884 (74.5) | 303 (25.5) | 1018 (85.8) | 168 (14.2) |
| TTP | ||||
| 1 mo | 204 (23.1) | 56 (18.5) | 218 (21.4) | 44 (26.2) |
| 2 mo | 137 (15.5) | 54 (17.8) | 163 (16.0) | 30 (17.9) |
| 3 mo | 84 (9.5) | 44 (14.5) | 115 (11.3) | 12 (7.1) |
| 4 mo | 60 (6.8) | 28 (9.2) | 76 (7.5) | 12 (7.1) |
| 5 mo | 47 (5.3) | 12 (4.0) | 50 (4.9) | 9 (5.4) |
| 6 mo | 34 (3.8) | 11 (3.6) | 37 (3.6) | 8 (4.8) |
| >6 mo | 318 (36.0) | 98 (32.3) | 359 (35.3) | 53 (31.5) |
| Unadjusted FOR (95% CI) | Reference | 1.06 (0.88–1.28) | Reference | 1.10 (0.87–1.39) |
| Adjusted FOR Model 1 (95% CI)a | Reference | 1.09 (0.90–1.31) | Reference | 1.12 (0.89–1.41) |
| Adjusted FOR Model 2 (95% CI)b | Reference | 1.08 (0.90–1.31) | Reference | 1.13 (0.89–1.42) |
a
Models adjusted for age and BMI.
b
Models adjusted for age, BMI, and treatment assignment (LDA vs placebo).